Valnivudine - ContraVir Pharmaceuticals

Drug Profile

Valnivudine - ContraVir Pharmaceuticals

Alternative Names: FV-100; Valnivudine

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University; FermaVir Pharmaceuticals; Rega Institute for Medical Research
  • Developer ContraVir Pharmaceuticals
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Herpes zoster; Postherpetic neuralgia

Most Recent Events

  • 20 Dec 2017 ContraVir Pharmaceuticals terminates a phase III trial in Postherpetic neuralgia (Prevention) in USA (PO) (NCT02412917)
  • 03 Mar 2016 adverse events data from a phase III in Herpes zoster released by ContraVir Pharmaceuticals
  • 02 Nov 2015 ContraVir completes a phase I pharmacokinetics trial in Healthy volunteers in USA (NCT02322957)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top